Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$110.76 USD
-0.53 (-0.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $110.81 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
JAZZ 110.76 -0.53(-0.48%)
Will JAZZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JAZZ
Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Jazz (JAZZ) Up 1.1% Since Last Earnings Report?
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Other News for JAZZ
Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Jazz Pharmaceuticals presents updated Phase 2 data for zanidatamab
Stock moves reflect downgrade for US economic growth outlook - Goldman